NIKKEI 225
33,431.51 -55.39 (-0.17%) HANG SENG
16,830.30 -212.60 (-1.25%) CRUDE OIL
74.84 +0.77 (+1.04%) GOLD FUTURES
2,137.10 +47.40 (+2.27%) DOW
36,245.50 +294.60 (+0.82%) Bitcoin GBP
31,537.02 +474.16 (+1.53%)
Myriad Genetics, Inc. (0K3W.L)
| Previous close | 16.25 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 163 |
| Market cap | 12.396M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksHere's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
GlobeNewswireMyriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby’s predicted
ZacksMyriad Genetics (MYGN) Expands Pharma Services With New Pact
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
